Stay updated with breaking news from Nasdaq Uthr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) Director Christopher Causey sold 2,240 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now directly owns 4,185 shares in the company, valued at […]
United Therapeutics (NASDAQ:UTHR – Get Free Report) had its price target boosted by analysts at The Goldman Sachs Group from $218.00 to $240.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would indicate a potential downside of […]
United Therapeutics (NASDAQ:UTHR – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54, Briefing.com reports. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had […]
Jackson Creek Investment Advisors LLC bought a new position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,106 shares of the biotechnology company’s stock, valued at approximately $683,000. Several other institutional […]
United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among […]